russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2021-4573russjcardiol-4573Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWРоль метаболизма гомоцистеина в развитии эндотелиальной дисфункции и артериальной гипертензии у больных множественной миеломойRole of homocysteine metabolism in the development of endothelial dysfunction and hypertension in patients with multiple myelomahttps://orcid.org/0000-0003-0645-7645ДавыдкинИ. Л.DavydkinI. L.

Давыдкин Игорь Леонидович — доктор медицинских наук, профессор, лауреат премии Правительства РФ, заведующий кафедрой госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара.

Samara.

dagi2006@rambler.ruhttps://orcid.org/0000-0002-6281-6385МордвиноваЕ. В.MordvinovaE. V.

Мордвинова Елизавета Владимировна — ассистент, очный аспирант кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара.

SPIN-код: 1601-3173

Samara.

liza.mordvinova.94@mail.ruhttps://orcid.org/0000-0002-5378-5687КузьминаТ. П.KuzminaT. P.

Кузьмина Татьяна Павловна — кандидат медицинских наук, ассистент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара.

Samara.

tatyana_kuzmina_91@bk.ruhttps://orcid.org/0000-0003-3170-1881НаумоваК. В.NaumovaK. V.

Наумова Ксения Викторовна — кандидат медицинских наук, ассистент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара.

Samara.

senechka.naumova@rambler.ruhttps://orcid.org/0000-0001-5545-1886ФатенковаЕ. С.FatenkovaE. S.

Кандидат медицинских наук, доцент кафедры госпитальной терапии с курсами поликлинической терапии и трансфузиологии.

Самара.

Samara.

Самарский государственный медицинский университет Минздрава РоссииРоссияSamara State Medical UniversityRussian Federation202126122021264SОбразование45734573Copyright © Давыдкин И.Л., Мордвинова Е.В., Кузьмина Т.П., Наумова К.В., Фатенкова Е.С., 20222022Давыдкин И.Л., Мордвинова Е.В., Кузьмина Т.П., Наумова К.В., Фатенкова Е.С.Davydkin I.L., Mordvinova E.V., Kuzmina T.P., Naumova K.V., Fatenkova E.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/4573

Статья посвящена современному представлению о развитии эндотелиальной дисфункции, роли гипергомоцистеинемии и, как следствие, артериальной гипертензии у пациентов с множественной миеломой, получающих полихимиотерапию. Учитывая, что возможности стандартного обследования не позволяют идентифицировать субклиническую дисфункцию эндотелия, необходимо использование специфических методик, в частности определение уровня гомоцистеина для мониторинга функции эндотелиоцитов.

Целью данного обзора является обобщение современных представлений об этиологии артериальной гипертензии и перспективах выявления ранних, субклинических изменений функции эндотелия, в т.ч. у пациентов с множественной миеломой.

Оценка наличия эндотелиальной дисфункции может быть полезна для определения именно субклинических стадий сердечно-сосудистой патологии с целью стратификации риска развития сердечно-сосудистых осложнений у пациентов, получающих химиотерапевтическое лечение.

The article is devoted to the modern understanding of endothelial dysfunction development, the role of hyperhomocysteinemia, and, as a consequence, hypertension in patients with multiple myeloma receiving multiagent chemotherapy. Considering that the potential of a standard examination does not allow identifying subclinical endothelial dysfunction, using specific techniques is necessary, in particular, to determine the homocysteine level to monitor the endothelial function.

The aim of this review was to summarize the current understanding of hypertension etiology and prospects for detecting early, subclinical endothelial changes, including in patients with multiple myeloma.

Assessment of endothelial dysfunction can be useful for detecting precisely the subclinical cardiovascular disease in order to stratify the risk of developing cardiovascular events in patients receiving multiagent chemotherapy.

эндотелийэндотелиальная дисфункцияартериальная гипертензиягомоцистеинMTHFRММР-2ММР-9H2Sмножественная миеломаendotheliumendothelial dysfunctionhypertensionhomocysteineMTHFRMMP-2MMP-9H2Smultiple myelomaReferencesМенделеева Л. П., Вотякова О. М., Рехтина И. Г. и др.; Ассоциация онкологов России, Национальное гематологическое общество, Общество онкогематологов. Российские клинические рекомендации по диагностике и лечению множественной миеломы. Москва. 2020. 222 с.Mendeleeva LP, Votyakova OM, Rekhtina IG, et al.; Association of Oncologists of Russia, National Hematological Society, Society of Oncohematologists. Russian clinical guidelines for the diagnosis and treatment of multiple myeloma. Moscow. 2020. р. 222. (In Russ.)Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: Cancer J Clin. 2016;66:7-30. doi:10.3322/caac.21332.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: Cancer J Clin. 2016;66:7-30. doi:10.3322/caac.21332.Давыдкин И. Л., Мордвинова Е. В., Кузьмина Т. П. Инфекционные осложнения при множественной миеломе в условиях современной эпидемиологической обстановки: обзор литературы. Клиническая онкогематология. 2021;14(3):386-90. doi:10.21320/2500-2139-2021-14-3-386-390.Davydkin IL, Mordvinova EV, Kuz'mina TP. Infectious complications in multiple myeloma in the current epidemiological setting: a literature review. Clinical oncohematology. 2021;14(3):386-90. (In Russ.) doi:10.21320/2500-2139-2021-14-3-386-390.Heitner SB, Minnier J, Naher A, et al. Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity. Scott Clinical Lymphoma, Myeloma & Leukemia. 2018;18(12):796-802. doi:10.1016/j.clml.2018.08.004.Heitner SB, Minnier J, Naher A, et al. Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity. Scott Clinical Lymphoma, Myeloma & Leukemia. 2018;18(12):796-802. doi:10.1016/j.clml.2018.08.004.Berliner D, Beutel G, Bauersachs J, et al. Echocardiography and biomarkers for the diagnosis of cardiotoxicity. Herz. 2020;45(7):637-44. doi:10.1007/s00059-020-04957-5.Berliner D, Beutel G, Bauersachs J, et al. Echocardiography and biomarkers for the diagnosis of cardiotoxicity. Herz. 2020;45(7):637-44. doi:10.1007/s00059-020-04957-5.Kistler KD, Kalman J, Sahni G, et al. Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study Clinical Lymphoma. Myeloma & Leukemia.2017;17(2):89-96.e3. doi:10.1016/j.clml.2016.11.009.Kistler KD, Kalman J, Sahni G, et al. Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study Clinical Lymphoma. Myeloma & Leukemia.2017;17(2):89-96.e3. doi:10.1016/j.clml.2016.11.009.Khan AA, Thomas GN, Lip GYH, et al. Endothelial function in patients with atrial Fibrillation. Annals of Medicine. 2020;52(1-2):1-11. doi:10.1080/07853890.2019.1711158.Khan AA, Thomas GN, Lip GYH, et al. Endothelial function in patients with atrial Fibrillation. Annals of Medicine. 2020;52(1-2):1-11. doi:10.1080/07853890.2019.1711158.Dawes MG, Bartlett G, Coats AJ, et al. Comparing the effects of white coat hypertension and sustained hypertension on mortality in a UK primary care setting. Ann Fam Med. 2008;6(5):390-6. doi:10.1370/afm.865.Dawes MG, Bartlett G, Coats AJ, et al. Comparing the effects of white coat hypertension and sustained hypertension on mortality in a UK primary care setting. Ann Fam Med. 2008;6(5):390-6. doi:10.1370/afm.865.Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol — Advances in Internal Medicine. 2017;956:511-40. doi:10.1007/5584_2016_90.Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension. Adv Exp Med Biol — Advances in Internal Medicine. 2017;956:511-40. doi:10.1007/5584_2016_90.Davydkin IL, Kuzmina TP, Naumova KV, et al. Endothelial dysfunction in patients with lymphoproliferative disorders and its changes in the course of polychemotherapy. Russian Open Medical Journal. 2020;9:e0309. doi:10.15275/rusomj.2020.0309.Davydkin IL, Kuzmina TP, Naumova KV, et al. Endothelial dysfunction in patients with lymphoproliferative disorders and its changes in the course of polychemotherapy. Russian Open Medical Journal. 2020;9:e0309. doi:10.15275/rusomj.2020.0309.Маргиева Т. В., Сергеева Т. В. Участие маркёров эндотелиальной дисфункции в патогенезе хронического гломерулонефрита. Вопр. соврем. педиатр. 2006;5(3):22-30.Margieva TV, Sergeeva TV. The involvement of endothelial dysfunction markers in the pathogenesis of chronic glomerulonephritis. Voprosy sovremennoy pediatrii. 2006;5(3):22-30. (In Russ.)George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am. J. Hypertens. 2011;24(29):964-9. doi:10.1038/ajh.2011.99.George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am. J. Hypertens. 2011;24(29):964-9. doi:10.1038/ajh.2011.99.Rosenthal A, Luthi J, Behlolavek M. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6:e384. doi:10.1038/bcj.2015.112.Rosenthal A, Luthi J, Behlolavek M. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6:e384. doi:10.1038/bcj.2015.112.Cornell RF, Ky B, Weiss BM, et al. Prospective study of cardiac events during protea-some inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019:JCO.19.00231. doi:10.1200/JCO.19.00231.Cornell RF, Ky B, Weiss BM, et al. Prospective study of cardiac events during protea-some inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019:JCO.19.00231. doi:10.1200/JCO.19.00231.Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. doi:10.1016/S0140-6736(05)17741-1.Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. doi:10.1016/S0140-6736(05)17741-1.Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-60. doi:10.1016/S0140-6736(12)61766-8.Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-60. doi:10.1016/S0140-6736(12)61766-8.Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-62.Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-62.Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) Guidelines for the Management of Arterial Hypertension. Vasc Health Risk Manag. 2007;3(6):783-95.Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) Guidelines for the Management of Arterial Hypertension. Vasc Health Risk Manag. 2007;3(6):783-95.Rossman MJ, Kaplon RE, Hill SD, et al. Endothelial cell senescence with aging in healthy humans: prevention by habitual exercise and relation to vascular endothelial function. Am J Physiol Circ Physiol. 2017;313(5):H890-H895. doi:10.1152/ajpheart.00416.2017.Rossman MJ, Kaplon RE, Hill SD, et al. Endothelial cell senescence with aging in healthy humans: prevention by habitual exercise and relation to vascular endothelial function. Am J Physiol Circ Physiol. 2017;313(5):H890-H895. doi:10.1152/ajpheart.00416.2017.Hohensinner PJ, Kaun C, Buchberger E, et al. Age intrinsic loss of telomere protection via TRF1 reduction in endothelial cells. Biochim Biophys Acta — Mol Cell Res. 2016;1863(2):360-7. doi:10.1016/J.BBAMCR.2015.11.034.Hohensinner PJ, Kaun C, Buchberger E, et al. Age intrinsic loss of telomere protection via TRF1 reduction in endothelial cells. Biochim Biophys Acta — Mol Cell Res. 2016;1863(2):360-7. doi:10.1016/J.BBAMCR.2015.11.034.Donato AJ, Morgan RG, Walker AE, et al. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol. 2015;89(Pt B):122-35. doi:10.1016/j.yjmcc.2015.01.021.Donato AJ, Morgan RG, Walker AE, et al. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol. 2015;89(Pt B):122-35. doi:10.1016/j.yjmcc.2015.01.021.Uryga AK, Bennett MR. Ageing induced vascular smooth muscle cell senescence in atherosclerosis. J Physiol. 2016;594(8):2115-24. doi:10.1113/JP270923.Uryga AK, Bennett MR. Ageing induced vascular smooth muscle cell senescence in atherosclerosis. J Physiol. 2016;594(8):2115-24. doi:10.1113/JP270923.Heckmann MB, Doroudgar Sh, Katus HA, et al. Cardiovascular adverse events in multiple myeloma patients. J Thorac Dis. 2018;10(Suppl 35):S4296-S4305. doi:10.21037/jtd.2018.09.87.Heckmann MB, Doroudgar Sh, Katus HA, et al. Cardiovascular adverse events in multiple myeloma patients. J Thorac Dis. 2018;10(Suppl 35):S4296-S4305. doi:10.21037/jtd.2018.09.87.Castro MM, Tanus-Santos JE. Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations. Curr Drug Targets. 2013;14(3):335-43.Castro MM, Tanus-Santos JE. Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations. Curr Drug Targets. 2013;14(3):335-43.Harvey A, Montezano AC, Lopes RA, et al. Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications. Can J Cardiol. 2016;32:659-68.Harvey A, Montezano AC, Lopes RA, et al. Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications. Can J Cardiol. 2016;32:659-68.Theocharis AD, Skandalis SS, Gialeli C, et al. Extracellular matrix structure. Adv. Drug Deliv. Rev. 2016;97:4-27. doi:10.1016/j.addr.2015.11.001.Theocharis AD, Skandalis SS, Gialeli C, et al. Extracellular matrix structure. Adv. Drug Deliv. Rev. 2016;97:4-27. doi:10.1016/j.addr.2015.11.001.Kesh K, Subramanian L, Ghosh N, et al. Association of MMP7 -181A^G promoter polymorphism with gastric cancer risk: Influence of nicotine in differential allele-specific transcription via increased phosphorylation of cAMP-response element-binding protein (CREB). J Biol Chem. 2015;290:14391-406. doi:10.1074/jbc.M114.630129.Kesh K, Subramanian L, Ghosh N, et al. Association of MMP7 -181A^G promoter polymorphism with gastric cancer risk: Influence of nicotine in differential allele-specific transcription via increased phosphorylation of cAMP-response element-binding protein (CREB). J Biol Chem. 2015;290:14391-406. doi:10.1074/jbc.M114.630129.Radosinska J, Barancik M, Vrbjar N. Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Med. 2017;59:241-53. doi:10.23736/S0031-0808.17.03321-3.Radosinska J, Barancik M, Vrbjar N. Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Med. 2017;59:241-53. doi:10.23736/S0031-0808.17.03321-3.Yabluchanskiy A, Ma Y, Iyer RP, et al. Matrix Metalloproteinase-9: Many Shades of Function in Cardiovascular Disease. Physiology. 2013;28:391-403. doi:10.1152/physiol.00029.2013.Yabluchanskiy A, Ma Y, Iyer RP, et al. Matrix Metalloproteinase-9: Many Shades of Function in Cardiovascular Disease. Physiology. 2013;28:391-403. doi:10.1152/physiol.00029.2013.Raffetto JD, Khalil RA. Matrix Metalloproteinases and their Inhibitors in Vascular Remodeling and Vascular Disease. Biochem Pharmacol. 2008;75:346-59. doi:10.1016/j.bcp.2007.07.004.Raffetto JD, Khalil RA. Matrix Metalloproteinases and their Inhibitors in Vascular Remodeling and Vascular Disease. Biochem Pharmacol. 2008;75:346-59. doi:10.1016/j.bcp.2007.07.004.Martinez-Lemus LA, Galinanes EL. Matrix metalloproteinases and small artery remodeling. Drug Discov Today Dis Models. 2011;8:21-8. doi:10.1016/j.ddmod.2011.06.002.Martinez-Lemus LA, Galinanes EL. Matrix metalloproteinases and small artery remodeling. Drug Discov Today Dis Models. 2011;8:21-8. doi:10.1016/j.ddmod.2011.06.002.Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation. 1995;91:1161-74. doi:10.1161/01.cir.91.4.1161.Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation. 1995;91:1161-74. doi:10.1161/01.cir.91.4.1161.Yi X, Zhou Y, Jiang D, et al. Efficacy of folic acid supplementation on endothelial function and plasma homocysteine concentration in coronary artery disease: a metaanalysis of randomized controlled trials. Exp Ther Med. 2014;7(5):1100-10. doi:10.3892/etm.2014.1553.Yi X, Zhou Y, Jiang D, et al. Efficacy of folic acid supplementation on endothelial function and plasma homocysteine concentration in coronary artery disease: a metaanalysis of randomized controlled trials. Exp Ther Med. 2014;7(5):1100-10. doi:10.3892/etm.2014.1553.Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2002;156:1105-13. doi:10.1093/aje/kwf157.Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2002;156:1105-13. doi:10.1093/aje/kwf157.Vianna AC, Mocelin AJ, Matsuo T, et al. Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int. 2007;11:210-6. doi:10.1111/j.1542-4758.2007.00171.x.Vianna AC, Mocelin AJ, Matsuo T, et al. Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int. 2007;11:210-6. doi:10.1111/j.1542-4758.2007.00171.x.Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202-6. doi:10.1136/bmj.325.7374.1202.Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202-6. doi:10.1136/bmj.325.7374.1202.Wang J, Du J, Fan R. Exploration of the risk factors of essential hypertension with hyperhomocysteinemia: A hospital-based study and nomogram analysis. Clinics (Sao Paulo). 2021;76:e2233. doi:10.6061/clinics/2021/e2233.Wang J, Du J, Fan R. Exploration of the risk factors of essential hypertension with hyperhomocysteinemia: A hospital-based study and nomogram analysis. Clinics (Sao Paulo). 2021;76:e2233. doi:10.6061/clinics/2021/e2233.Yang Q, He GW. Imbalance of Homocysteine and H2S: Significance, Mechanisms, and Therapeutic Promise in Vascular Injury. Oxidative Medicine and Cellular Longevity. 2019;7629673. doi:10.1155/2019/7629673.Yang Q, He GW. Imbalance of Homocysteine and H2S: Significance, Mechanisms, and Therapeutic Promise in Vascular Injury. Oxidative Medicine and Cellular Longevity. 2019;7629673. doi:10.1155/2019/7629673.Kumar M, Mahajan A, Sapehia D, et al. Effects of altered maternal folate and vitamin B12 on neurobehavioral outcomes in F1 male mice. Brain Res Bull. 2019;153:93-101. doi:10.1016/j.brainresbull.2019.07.031.Kumar M, Mahajan A, Sapehia D, et al. Effects of altered maternal folate and vitamin B12 on neurobehavioral outcomes in F1 male mice. Brain Res Bull. 2019;153:93-101. doi:10.1016/j.brainresbull.2019.07.031.Kumar M, Sandhir R. Hydrogen Sulfide Attenuates Hyperhomocysteinemia-Induced Mitochondrial Dysfunctions in Brain. Mitochondrion. 2019;50:158-69. doi:10.1016/j.mito.2019.11.004.Kumar M, Sandhir R. Hydrogen Sulfide Attenuates Hyperhomocysteinemia-Induced Mitochondrial Dysfunctions in Brain. Mitochondrion. 2019;50:158-69. doi:10.1016/j.mito.2019.11.004.Sen U, Sathnur PB, Kundu S, et al. H2S generation by cbs, cse, and 3mst gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. American Journal of Physiology-Cell Physiology. 2012;303(1):C41-51. doi:10.1152/ajpcell.00398.2011.Sen U, Sathnur PB, Kundu S, et al. H2S generation by cbs, cse, and 3mst gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. American Journal of Physiology-Cell Physiology. 2012;303(1):C41-51. doi:10.1152/ajpcell.00398.2011.Christine CW, Auinger P, Joslin A, et al. Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease. Mov Disord. 2018;33(5):762-70. doi:10.1002/mds.27301.Christine CW, Auinger P, Joslin A, et al. Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease. Mov Disord. 2018;33(5):762-70. doi:10.1002/mds.27301.MartbCarvajal AJ, Sola I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8):CD006612. doi:10.1002/14651858.MartbCarvajal AJ, Sola I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8):CD006612. doi:10.1002/14651858.Zhang Q, Li S, Li L, et al. Metformin Treatment and Homocysteine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2016;8(12):798. doi:10.3390/nu8120798.Zhang Q, Li S, Li L, et al. Metformin Treatment and Homocysteine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2016;8(12):798. doi:10.3390/nu8120798.Kawada T. Smoking, hyperhomocysteinemia, metabolic syndrome, and cardiovascular risk. Nutrition. 2021;81:111031. doi:10.1016/j.nut.2020.111031.Kawada T. Smoking, hyperhomocysteinemia, metabolic syndrome, and cardiovascular risk. Nutrition. 2021;81:111031. doi:10.1016/j.nut.2020.111031.Kang SS, Rosenson RS. Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease. Cardiovasc Drugs Ther. 2018;32(2):233-40. doi:10.1007/s10557-018-6790-1.Kang SS, Rosenson RS. Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease. Cardiovasc Drugs Ther. 2018;32(2):233-40. doi:10.1007/s10557-018-6790-1.Van Meurs JB, Pare G, Schwartz SM, et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr. 2013;98(3):668-76. doi:10.3945/ajcn.112.044545.Van Meurs JB, Pare G, Schwartz SM, et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr. 2013;98(3):668-76. doi:10.3945/ajcn.112.044545.Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288(16):2023-31. doi:10.1001/jama.288.16.2023.Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288(16):2023-31. doi:10.1001/jama.288.16.2023.Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of c irculating homocysteine concentrations. Genet Epidemiol. 1999;17(4):298-309. doi:10.1002/(SICI)1098-2272(199911)17:4<298::AID-GEPI5>3.0.CO;2-V.Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of c irculating homocysteine concentrations. Genet Epidemiol. 1999;17(4):298-309. doi:10.1002/(SICI)1098-2272(199911)17:4<298::AID-GEPI5>3.0.CO;2-V.Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis. 2001;157(2):451-6. doi:10.1016/s0021-9150(00)00739-5.Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis. 2001;157(2):451-6. doi:10.1016/s0021-9150(00)00739-5.

The authors declare that there are no conflicts of interest present.